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up, the differences to BT were not statistically significant. 
Overall age had a negative impact on EF preservation (cor-
rected for baseline IIEF).
Conclusion In our series, EF was adversely affected by 
each treatment modality. Considered overall, BT provided 
the best EF preservation in comparison to EBRT or RP.
Keywords Quality of life · Erectile dysfunction · 
Brachytherapy · Prostatectomy · Radiotherapy
Erektile Funktion nach Brachytherapie, externer 
Radiotherapie oder radikaler Prostatektomie bei 
Prostatakrebs-Patienten
Zusammenfassung
Hintergrund und Ziel Die externe Radiotherapie (EBRT), 
die radikale Prostatektomie (RP) sowie die Brachytherapie 
(BT) stellen Behandlungsoptionen für das lokalisierte 
Prostatakarzinom dar. Die erektile Dysfunktion (ED) ist 
eine häufige Nebenwirkung dieser Therapien. Unser Ziel 
war es, die penile erektile Funktion (EF) vor und nach BT, 
EBRT und RP mit Hilfe eines validierten, vom Patienten 
ausgefüllten Lebensqualitätsfragebogens aus einer 
prospektiven Datenbank zu beurteilen.
Material und Methoden Mit einer minimalen Nach-
beobachtungszeit von einem Jahr wurden 478 Patienten 
analysiert, die eine RP (n = 252), EBRT (n = 91) oder BT 
(n = 135) erhalten hatten und deren EF mit dem IIEF-5-
Score vor Therapie sowie nach 6 Wochen, 6 Monaten, nach 
einem Jahr und danach jährlich ermittelt worden sind.
Ergebnis Die größten therapiebedingten Unterschiede 
wurden bei Patienten ohne oder nur mit milder initialer 
ED beobachtet (IIEF-5 ≥ 17). Korrigiert für die EF und das 
Alter bei Therapie, war die BT mit höherem IIEF-5-Score 
Abstract
Background and purpose For localized prostate cancer, 
treatment options include external beam radiotherapy 
(EBRT), radical prostatectomy (RP), and brachytherapy 
(BT). Erectile dysfunction (ED) is a common side-effect. 
Our aim was to evaluate penile erectile function (EF) before 
and after BT, EBRT, or RP using a validated self-adminis-
tered quality-of-life survey from a prospective registry.
Material and methods Analysis included 478 patients un-
dergoing RP (n = 252), EBRT (n = 91), and BT (n = 135) with 
at least 1 year of follow-up and EF documented using IIEF-
5 scores at baseline, 6 weeks, 6 months, 1 year, and annually 
thereafter.
Results Differences among treatments were most pro-
nounced among patients with no or mild initial ED (IIEF-
5 ≥ 17). Overall, corrected for baseline EF and age, BT was 
associated with higher IIEF-5 scores than RP (+ 7.8 IIEF-5 
score) or EBRT (+ 3.1 IIEF-5 score). EBRT was associated 
with better IIEF-5 scores than RP (+ 4.7 IIEF-5 score). In 
patients undergoing EBRT or RP with bilateral nerve spar-
ing (NS), recovery of EF was observed and during follow-
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assoziiert als die RP (+ 7,8 IIEF-5-Score) oder die EBRT 
(+ 3,1 IIEF-5-Score). Die EBRT war mit einem besseren 
IIEF-5-Score assoziiert als die RP (+ 4,7 IIEF-5-Score). Bei 
Patienten mit bilateraler nervenschonender RP oder einer 
EBRT wurde eine Erholung der EF beobachtet; im Verlauf 
war der Unterschied zur BT nicht mehr statistisch signifikant. 
Insgesamt hatte ein höheres Alter einen negativen Einfluss 
auf die Erhaltung der EF (korrigiert für Ausgangs-EF).
Schlussfolgerung In unserer Serie verschlechterte sich die 
EF durch alle Therapieformen. Insgesamt bot die BT die 
beste EF-Erhaltung verglichen mit der EBRT oder RP.
Schlüsselwörter Lebensqualität · Erektile Dysfunktion · 
Brachytherapie · Prostatektomie · Radiotherapie
Prostate cancer remains the most common nondermato-
logic cancer affecting men in the Western world [1]. The 
optimal management strategy for patients with newly diag-
nosed clinically localized prostate cancer remains a matter 
of debate. Because of a lack of definitive evidence demon-
strating superiority in cure rates of one local treatment over 
another [2, 3], quality-of-life (QoL) parameters are even 
more important [4–6]. Functional and oncological outcomes 
should be considered in the evaluation of treatment success 
[3, 7]. Despite improvements in radiotherapy and prosta-
tectomy, erectile dysfunction (ED) among other adverse 
effects, is still common [8–11]. Although local treatments 
focus on cure, there is a need to include ED and possible 
recovery of potency in their assessment [7, 12], especially 
since patients’ decisions are driven by many factors other 
than cancer cure [13].
Our aim was to perform an intention-to-treat analysis 
from prospectively collected data from a single institution 
on the functional results associated with three different 
treatment modalities for localized prostate cancer. Patients 
underwent permanent I-125 low dose rate prostate brachy-
therapy (BT), external beam radiotherapy (EBRT), or radi-
cal prostatectomy (RP). In our study, we evaluated penile 
erectile function (EF) at baseline, and after treatment with 
a minimum follow-up of 12 months using a validated self-
administered patient quality-of-life survey; we subsequently 
determined the impact of clinical and treatment parameters. 
The five-item version (IIEF-5) of the 15-item International 
Index of Erectile Function (IIEF; [14]) was used to quantify 
ED [15].
Materials and methods
A total of 478 patients with at least 12 months of follow-
up and assessment of pretreatment EF determined using 
the IIEF-5 (range 1–25; [15, 16]) underwent LDR I-125 
BT with a prescribed dose of 145 Gy, EBRT with a median 
dose of 72 Gy (70–78 Gy; the target of treatment being the 
prostate and the base of the seminal vesicles) in 3D conven-
tional four-field technique or RP between 2005 and 2013 for 
mostly low–intermediate risk prostate cancer based on eligi-
bility to these treatments and treatment decision was based 
on patient preference. Of the 252 radical prostatectomies, 
65 were robot-assisted and the others were open. Follow-
up data were collected in a prospective registry at 6 weeks, 
6 months, 12 months, and annually thereafter. As a part of 
their follow-up patients were asked to complete an IIEF-5 
questionnaire. The median follow-up was 2 years.
The IIEF-5 score was graded as very severe (1–4), severe 
(5–7), moderate (8–11), mild to moderate (12–16), mild 
(17–21), and no ED (22–25) based on the published clas-
sification [14]. In addition, a cut-off score of 17 was used 
to differentiate no-to-mild ED and worse ED. An age of 65 
years, the median of our cohort, was used to differentiate 
younger from older patients.
Statistical analysis
Multinomial regression was used to explore the relationship 
between age, EF, and the choice of treatment. To examine the 
relationship between treatment and EF, linear mixed models 
with a random slope and intercept were used, adjusted for 
baseline EF and current age (< 65 vs. ≥ 65 years). Linear mod-
els were used to examine the effect of treatment on EF scores 
at 1, 2, and 3 years. Adjusted confidence intervals for differ-
ences between the treatments were computed from the regre- 
ssion models, and adjusted using the Holm correction [17].
All analyses were performed in the R programming lan-
guage (version 3.0.2; [18]). The package lme4 [19] was used 
to estimate the mixed models, while the multcomp pack-
age [20] was used to compute the p-values and confidence 
intervals. Box-and-whisker plots were used to represent the 
distribution of variables. Median values were denoted by a 
thick line, the box represented the upper and lower quartile. 
The vertical lines denote maximum and minimum values, 
excluding outliers. Outliers were defined as more than 3/2 
of upper quartile or less than 3/2 of lower quartile and were 
denoted as points. The database was approved by the local 
ethics committee (Ethics Committee St. Gallen).
Results
A summary of baselines characteristics is provided in 
Table 1. Younger patients and patients with better baseline 
EF were more likely to undergo BT than RP and more likely 
to undergo RP than EBRT. There was no statistically sig-
nificant interaction between age and baseline IIEF-5 score 
in terms of treatment choice (data not shown). Androgen 
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Differences between treatments were smaller but 
nonetheless significant among patients with worse ED 
(IIEF-5 < 17) at baseline. Thus, those treated with BT had 
an IIEF-5 that was on average 4.6 and 2.7 points higher dur-
ing overall follow-up than that in patients treated with RP 
and EBRT, respectively. Patients treated with EBRT had an 
IIEF-5 that was on average 1.8 higher than that in patients 
treated with RP (Table 2).
Nerve sparing (NS) was used in 45 % of radical prosta-
tectomies. Among patients treated with RP, there were no 
statistically significant differences in IIEF-5 between those 
receiving unilateral or no NS, even after adjusting for IIEF-5 
at baseline and age (Table 2). However, patients receiving 
bilateral NS had a significantly higher IIEF-5 than patients 
receiving both no or unilateral NS. For patients with mild 
to no ED at baseline, we observed a 0.7 point higher IIEF-5 
among those receiving unilateral vs no NS, and a 4.4 point 
higher IIEF-5 comparing patients receiving a bilateral and 
no NS. Among patients with a poor EF, there were no sig-
nificant differences between any of the nerve sparing strate-
gies (Table 2; Fig. 3).
For younger RP patients undergoing bilateral NS, recov-
ery at 3 years after treatment was comparable to recovery 
for younger patients undergoing EBRT (Fig. 2). Thus, com-
pared to baseline, younger RP patients undergoing bilateral 
NS had a mean decrease in EF of − 4.4 (95 % CI − 8.1 to 
− 0.8), compared to younger BT patients with a decrease of 
− 5.3 (95 % CI − 6.9 to − 3.6) and younger EBRT patients 
with a decrease of − 3.8 (95 % CI − 13.2 to 5.6). Generally, 
in patients with moderate to very severe posttreatment ED 
no improvement was observed (Fig. 3).
When 1-, 2-, and 3-year IIEF-5 scores were compared 
with baseline scores a stronger preservation of EF was 
observed among patients undergoing EBRT or BT as com-
pared with RP without bilateral NS, even after adjusting for 
baseline EF and age. At the 3-year follow-up EBRT and RP 
with bilateral NS were associated with worse EF than BT, 
but this difference was not statistically significant (Table 3).
Discussion
Our study results revealed that in a large proportion of men 
who undergo therapy with curative intent for localized pros-
tate cancer, ED will occur as an adverse effect. In our series, 
ED was more frequent after RP relative to EBRT or BT, 
with a proportion of younger patients showing recovery, 
independent of treatment modality. Overall, the best erectile 
function preservation throughout follow-up, independent of 
age, was provided by BT. RP with bilateral NS and EBRT 
were associated with good recovery in young patients with 
good baseline EF.
deprivation therapy was registered in less than 5 patients 
per treatment group during the first year after treatment, 
a few of these patients had started ADT before treatment 
(neoadjuvant, leading to low pre-treatment values). Only 17 
patients were taking medication for ED during the whole 
follow-up period; 12 in the radical prostatectomy group and 
5 in the brachytherapy group. The available IIEF-5 entries 
were 429, 358, and 275 at 1, 2 and 3 years, respectively, 
with similar drop-out rates across all patients groups and 
treatments.
While all treatment modalities were associated with a 
decrease in EF, the course of EF scores over time revealed 
a divergent effect (Fig. 1). Even after adjusting for baseline 
EF and age, the course of EF differed significantly depend-
ing on treatment modality. BT resulted in higher EF scores 
compared to RP and EBRT, while EBRT yielded higher EF 
scores compared to RP (Table 2 and 3).
Age was an important clinical predictor regarding the 
preservation of potency; thus, increasing age was associ-
ated with lower EF scores (Fig. 2). However, when ana-
lyzed separately for patients with no or mild ED at baseline 
(IIEF-5 ≥ 17) or worse, age was a significant predictor only 
for patients with worse ED (IIEF-5 < 17; Table 2).
For patients with mild to no ED (IIEF-5 ≥ 17) at baseline, 
differences in EF according to treatment modality persisted. 
Patients who received BT had IIEF-5 scores that were on 
average 9.1 points higher than those treated with RP, while 
patients treated with EBRT had IIEF-5 scores that were on 
average 6.9 points higher than those who received RP. We 
also observed a small, slightly nonsignificant difference 
between the BT and EBRT patients favoring the BT patients 
(Table 2).
Table 1 Summary statistics at baseline by type of treatment
Variable RP BT EBRT All
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n number of patients, BT brachytherapy, RP radical prostatectomy, 
EBRT external beam radiotherapy. IIEF-5 international index of 
erectile function.
aIn four patients Gleason score could not be determined because 
prostate cancer was diagnosed based on cytology.
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lap in confidence intervals. Unfortunately, similar to cancer 
outcomes, little information exists in terms of randomized 
trial data for the evaluation of sexual QoL measures follow-
ing RP, BT, or EBRT.
RP is known to cause immediate ED, after which recovery 
of potency typically occurs slowly or not at all [23, 24]. Uni-
lateral nerve-sparing was performed in 21 % of our patients 
undergoing surgery and 24 % received bilateral NS. The 
high incidence of ED after RP in our study is in accordance 
with data from a large randomized trial conducted by Wilt et 
al. [25] who reported an incidence of 81.1 % ED after nerve 
sparing surgery relative to 44.1 % in the observational arm. 
In a recent paper, Montorsi et al. [26] reported data from 
a randomized trial regarding the effects of tadalafil treat-
ment on recovery of EF following bilateral nerve-sparing 
RP. After bilateral nerve-sparing RP, 20.9, 16.9, and 19.1 % 
of patients (mean age 57.9 years; follow-up 9–13.5 months) 
in the tadalafil once daily, on demand, and placebo groups, 
respectively, achieved IIEF-5 scores ≥ 22 after a 6-week 
drug-free washout. An adjuvant radiotherapy trial (South 
Western Oncology Group 8794; [9]) indicated that only 7 % 
of men had intact EF function postprostatectomy and prera-
diotherapy. Summarizing these trials, it can be assumed that 
about 80–95 % of patients may suffer from ED immediately 
after RP.
ED is also a common sequelae of RT for prostate cancer, 
affecting approximately 35–55 % of patients after EBRT 
[27–29] and 25–50 % after BT [30–33]. Using a patient-
administered validated QoL instrument, Merrick et al. [31] 
showed that BT-induced ED occurred in 50 % of patients 
The optimal treatment for men with newly diagnosed 
clinically localized prostate cancer remains up for debate, 
which is due to a lack of contemporary prospective random-
ized studies comparing efficacy and side effects incorpo-
rating different therapies. Besides active surveillance for 
low-risk prostate cancers, EBRT, BT, and RP are all asso-
ciated with good long-term cancer control in early stage 
disease [21]. During the last decade increasing attention 
has focused on the relative toxicities of treatments in an 
effort to decrease treatment-related morbidity. Patient deci-
sions are often driven not by a focus on cancer cure, but 
by side effects and personal perceptions, including fear [13, 
21]. This underlines the importance of outcomes beyond 
survival. In addition to our investigation, several studies 
have shown, albeit in retrospective nonrandomized series, 
a negative influence on sexual function after completion of 
prostate cancer treatment.
Sanda et al. [22] conducted a prospective multicenter 
evaluation assessing outcomes from 1201 patients and 
625 spouses or partners before and after RP, BT, or EBRT. 
They noted that sexual QoL was adversely affected after 
each treatment as compared with baseline [22]. Besides 
being modality dependent, the etiology of posttreatment 
ED is considered to be multifactorial. The wide ranges of 
reported ED likely reflect differences in follow-up, patient 
selection, treatment technique, and the mode of data collec-
tion. However, even within trials the range of outcomes can 
vary considerably, in a population-based analysis by Carls-
son et al. [11], odds ratios favored radiotherapy over RP for 
erectile dysfunction (1.56 vs. 2.29), however with an over-
Table 2 Linear mixed model with random slope and intercept for erectile function (EF) at 1.5–36 months for all patients (upper part of table) and 
RP patients only (lower part of table). Confidence intervals for differences between the three treatments were adjusted using the Holm correction. 
Values show estimate and 95 % confidence interval (95% CI)
Predictor All No or mild ED (IIEF-5 ≥ 17) Worse ED (IIEF-5 < 17)
Estimate 95 % CI Estimate 95 % CI Estimate 95 % CI
Baseline EF 0.411 0.346–0.476 0.650 0.410–0.890 0.315 0.209–0.422
Age (≥ 65) − 1.446 − 2.411 to 0.482 − 0.961 − 2.250 to 0.327 − 1.866 − 3.068 to 
− 0.665
BT vs. RP 7.799 6.564–9.034 9.092 7.506–10.677 4.573 2.877–6.269
EBRT vs. RP 4.740 3.226–6.254 6.929 4.459–9.398 1.845 0.271–3.419
BT vs. EBRT 3.059 1.348–4.771 2.163 − 0.419 to 4.745 2.728 0.767–4.690
Intercept − 0.888 − 0.699 to 2.155 − 7.036 − 12.274 to 
− 1.797
1.9564 0.487–3.426
Predictor All RP No or mild ED (IIEF-5 ≥ 17) Worse ED (IIEF-5 < 17)
Estimate 95 % CI Estimate 95 % CI Estimate 95 % CI
Baseline EF 0.174 0.092–0.257 0.058 − 0.238 to 0.354 0.213 0.081–0.345
Age (≥ 65) − 1.358 − 2.454 to 
− 0.263
− 1.114 − 2.610 to 0.382 − 1.764 − 3.100 to 
− 0.428
unilateral vs. no NS 0.370 − 1.226 to 1.966 0.683 − 1.452 to 2.818 0.013 − 2.118 to 2.143
bilateral vs. no NS 3.302 1.527–5.076 4.391 2.016–6.766 0.983 − 1.296 to 3.262
bilat. vs. unilateral 2.932 0.870–4.993 3.708 1.005–6.411 0.971 − 1.775 to 3.716
Intercept 2.503 0.804–4.202 4.596 − 1.705 to 10.898 2.707 0.913–4.501
BT brachytherapy, RP radical prostatectomy, EBRT external beam radiotherapy. IIEF-5 international index of erectile function, ED erectile 
dysfunction, EF erectile function, NS nerve sparing.
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term functional outcomes involving > 10 years follow-up 
after different treatment modalities. In 2013, the Prostate 
Cancer Outcomes Study [8] reported on data from a cohort 
comprising 1655 men in whom localized prostate cancer 
had been diagnosed in 1994 or 1995, between the ages of 55 
and 74 years, and who had undergone either surgery (1164 
men) or EBRT (491 men). Patients undergoing RP were 
more likely to have ED at 2 years (OR 3.46) and 5 years 
(OR 1.96), but no significant between-group difference was 
noted at 15 years. Treatment-related long-term effects on 
ED should be discussed with caution. The Massachusetts 
Male Aging Study [38] showed that the incidence rate of ED 
in the normal male population between 60 and 69 years of 
age was 4.6 % per year.
In concordance with previous trials [39–41], in our study 
age at diagnosis was found to be an important clinical pre-
dictor for potency preservation; however, when adjusted 
for a baseline IIEF-5 of at least ≥ 17 (no/mild ED), age was 
no longer an adverse factor (Table 2). We demonstrated 
that preservation of EF based on baseline IIEF scores was 
dependent on treatment modality. At the 1-year follow-up, 
the treatment-related difference in occurrence of ED was 
most pronounced in patients with good baseline EF, favor-
ing BT and EBRT relative to RP.
There were a number of limitations associated with the 
current study. First, although the data were collected pro-
spectively, it was not a randomized trial. Second, the sample 
size of this prospective, single-center study was limited as 
compared with the sample sizes evaluated in other series, 
especially those with single arms. Third, the follow-up 
in this investigation was limited and a reliable estima-
tion regarding EF beyond the limited follow-up time was 
impossible.
Improvements and developments in treatments including 
modern IMRT techniques and prostatectomy techniques, 
including their learning curves, are not addressed in this 
report.
at 3 years. In 2014, Ong et al. [33] reported outcomes for 
366 potent (IIEF ≥ 17) patients undergoing BT with EF 
measured by IIEF-5. At 2 and 5 years, the prevalence of 
moderate–severe ED was 46 and 53 %, respectively. Fol-
lowing permanent prostate BT, Taira et al. [34] reported a 
7-year actuarial rate of potency preservation of 55.6 %, with 
a median postimplant IIEF of 22 in potent patients. Potent 
patients were statistically younger, had a higher pre-implant 
IIEF, were less likely to be diabetic, and were more likely 
to report nocturnal erections [34]. A matched-pair study 
compared erectile dysfunction between patients undergo-
ing dose-escalated image-guided radiotherapy (IMRT) and 
high dose-rate interstitial brachytherapy (HDR) revealed no 
overall difference in erectile function with a 2-year median 
follow-up [35].
Few prospective series, comparing different treatment 
modalities, have been reported using validated QoL instru-
ments and incorporating pretreatment functional data. For 
example, Litwin et al. [36] evaluated 580 men with clini-
cally localized prostate cancer who were undergoing RP 
(n = 307), EBRT (n = 78), or BT (n = 90). These investiga-
tors found that men who underwent RP had worse sexual 
function than either radiation cohort. However, beyond 
8 months after treatment the proportion of men reporting 
severe sexual bother did not differ significantly among treat-
ment groups, largely due to an improvement in the sexual 
bother score among RP patients over time. Data from the 
Spanish Multicentric Study of Clinically Localized Prostate 
Cancer [37] showed that sexual deterioration was greater 
among surgical patients. Few studies have reported on long-
Table 3 Linear model adjusted for baseline erectile function (EF) and 
age with EF at 12, 24, and 36 months as dependent variables. Values 
show estimate and confidence intervals (CI) for differences between 
the treatments, which were adjusted using the Holm correction
Comparison EF at 12 
months esti-
mate (95 % 
CI)
EF at 24 
months esti-
mate (95 % 
CI)
EF at 36 
months esti-
mate (95 % 
CI)
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BT brachytherapy, RP radical prostatectomy, EBRT external beam 
radiotherapy. IIEF-5 international index of erectile function, NS 
nerve sparing.
Fig. 1 Boxplots of IIEF-5 scores at baseline and follow-up for differ-
ent treatment modalities. RP radical prostatectomy, BT brachytherapy, 
EBRT external beam radiotherapy
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cancer [47] which has been shown to be associated with bet-
ter long-term erectile function [48]. Considering all these 
shortcomings, a risk for bias cannot be excluded; unknown 
factors may have influenced treatment decision, baseline 
ED as well the effect of individual treatments on EF.
Our current study also had a number of notable strengths. 
First, evaluation was performed using a validated QoL 
instrument and incorporated pretreatment functional data. 
In comparison to many other series we were able to include 
In addition, prospective data collection did not include 
other risk factors that may be associated with erectile func-
tion, such as smoking history, concomitant medication, 
diabetes mellitus, or other comorbidities [42–45]. Patient 
expectations and fears are also relevant for decision making 
and subjective outcome evaluation; these were not addressed 
[13]. Details of dose distribution known to be relevant, such 
as the dose to the penile bulb were also not included [46]. 
Currently many centers are implementing IMRT in prostate 
Fig. 3 Boxplots of IIEF scores 
for baseline (preoperative) erec-
tile function and during follow-up 
for different treatment modalities. 
Patients with worse baseline EF 
generally did not recover. EF 
erectile function, RP radical pros-
tatectomy, BRA brachytherapy, 
EBRT external beam radio-
therapy, unilat. unilateral, bilat. 
bilateral, NS nerve sparing
 
Fig. 2 IIEF-5 -scores for baseline 
(preoperative) EF and during 
follow-up for the different treat-
ment modalities and nerve spar-
ing strategies. Generally, the best 
EF preservation was observed in 
patients undergoing BT. Young 
patients undergoing EBRT or 
bilateral NS RP displayed partial 
EF recovery during follow-up. 
EF erectile function, RP radical 
prostatectomy, BT brachytherapy, 
EBRT external beam radiothera-
py, NS nerve sparing
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15. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM (1999) 
Development and evaluation of an abridged, 5-item version of the 
International Index of Erectile Function (IIEF-5) as a diagnostic 
tool for erectile dysfunction. Int J Impot Res 11:319–326
16. Ramanathan R, Mulhall J, Rao S, Leung R, Martinez Salamanca 
JI, Mandhani A, Tewari A (2007) Predictive correlation between 
the International Index of Erectile Function (IIEF) and Sexual 
Health Inventory for Men (SHIM): implications for calculating a 
derived SHIM for clinical use. J Sex Med 4:1336–1344
17. Holm S (1979) A simple sequentially rejective multiple test proce-
dure. Scand J Stat 6:65–70
18. R Core Team (2013) R: a language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna
19. Bates D Mächler M, Bolker B (2013) lme4: Linear mixed-effects 
models using S4 classes. R package version 0.999999-2
20. Hothorn T, Bretz F, Westfall P (2008) Simultaneous inference in 
General Parametric Models. Biom J 50:346–336
three treatment modalities (BT, EBRT, and RP). The median 
follow-up was 24 months. According to the literature the 
follow-up should be about 24 months, after which time the 
development of ED tends to stabilize, at least for the follow-
ing few years [8, 27, 29, 49]. Both surgical and radiotherapy 
patients were evaluated during the same time period with 
the same standardized questionnaire at the same institution.
Conclusion
In our series, relative to baseline, EF was adversely affected 
by each treatment modality. EF was best preserved after 
BT, remaining superior to EBRT and RP during 36 months 
of follow-up. EBRT had slightly better outcomes when 
compared with RP, this difference being most pronounced 
when patients undergoing RP did not receive bilateral nerve 
sparing. The treatment-related differences in occurrence of 
ED was most pronounced in younger patients (< 65 years 
of age) with a good baseline EF favoring BT over other 
modalities. Independent of age, patients with good baseline 
function had the best EF preservation with BT. Although not 
conclusive, these data enhance our existing understanding 
of treatment-induced ED, which is essential when counsel-
ling patients on their treatment options.
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